BerGenBio

BerGenBio ASA: Increase of share capital, exercise of share options and disclosure of trade by primary insider

Bergen, Norway, 11 June 2021

The Board of Directors in BerGenBio ASA (the "Company") (OSE: BGBIO) have, to

fulfil the Company's obligations under the share option agreements and in

accordance with the authorization granted by the general meeting on 19 March

2021, today resolved to increase the Company's share capital by NOK 7,500 by

issuance of 75,000 new shares. The new shares are subscribed for by option owner

who wishes and are entitled to exercise options in accordance with the Company's

option scheme. Each option gives a right to receive one share in the Company.

The subscription price is in accordance with the prevailing options price

pursuant to the Company´s option scheme NOK 10.62 per share.

The 75,000 options are exercised by primary insider Richard Godfrey (CEO) and

the options are granted 13 June 2013 and expiry on 13 June 2021. Primary insider

notification pursuant to the market abuse regulation article 19 is attached.

The primary insider has transferred his rights to receive shares resulting from

the exercise of options to a third party. The third party has sold the shares at

a price of NOK 25.67 per share.

Following the exercise, primary insider Richard Godfrey are holding 1,684,978

options in the Company of which 1,096,462 is vested, in addition to 21,005

shares in the Company through Gnist Holding AS.

The capital increase is expected to be registered within 7 days, and following

the issuance of the new shares, the issued share capital of BerGenBio ASA will

be NOK 8,796,275.50 consisting of 87,962,755 shares, each with a par value of

NOK 0.10.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

Rune Skeie

CFO, BerGenBio ASA

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to the

market abuse regulation article 19 and section 5-12 of the Norwegian Securities

Trading Act.

AI Terminal